Unprecedented drug design minimising side effects
HRI has developed an unprecedented drug design strategy that tailors drugs with fatty acids to minimise side effects.
Global media interest in HRI’s breakthrough anti-clotting drug for COVID-19
The revolutionary new anti-clotting medicine developed by HRI has attracted global media interest due to its far-reaching impact.
HRI researchers on cusp of worldwide breakthrough in COVID-19 treatment
Researchers at HRI believe they may hold the key to controlling the deadly blood clots caused by COVID-19.
Why our hearts fail
Scientists at HRI and The University of Sydney have made new heart failure discoveries in an innovative world-first project examining cryo-preserved human hearts.
HRI announces novel anti-clotting drug to help critically ill COVID-19 patients
HRI is on the precipice of a significant research breakthrough for the treatment of one of the major life-threatening complications of the novel coronavirus (COVID-19), microscopic blood clots.
Cardiovascular Medical Devices Group reviews next-generation surfaces
HRI's Cardiovascular Medical Devices Group reviews next-generation liquid-infused surfaces that could be used to improve medical devices like heart bypass machines.
HRI undertakes critical research into COVID-19-related heart disease
The Heart Research Institute, in partnership with major NSW hospitals, universities, and other research institutions, is striving to unravel the deadly link between the coronavirus (COVID-19) and cardiovascular disease.
Revealed: The molecule messing with your gym workout
Research by HRI explains why some people fail to shed pounds and lower cholesterol even when eating well and exercising hard.
World-leading researcher in atherosclerosis to join HRI
World-leading researcher in atherosclerosis, Dr Tessa Barrett, will lead a new research group at HRI, funded by a prestigious NSW Cardiovascular Elite Postdoctoral Researcher Grant from NSW Health and HRI’s Robert Edward Gough Fellowship.